Do you discontinue an aromatase inhibitor in a patient if they have a cardiac event while on the drug?
Does the presence of other cardiac risk factors change your recommendation?
Community PollStarted
How would you manage a patient with high-risk breast cancer who has a cardiac event while on adjuvant aromatase inhibitor?
59 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Ohio State University
Answered on
Randomized clinical trials and several meta-analyses that compared tamoxifen with aromatase inhibitors (Khosrow-Khavar et al., PMID 32065766 is a more recent one) demonstrated statistically significant increase in the rate of cardiovascular events in women taking aromatase inhibitors although the ab...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Private Practice and Digital Health
Answered on
The decision to continue or discontinue endocrine therapy in a patient with breast cancer needs to take into account the dynamic interplay with other comorbidities and competing causes of mortality.
It’s not so much whether an AI is contributing to the cardiac event, which is less likely in real-ti...
Join for free or sign in to see the full answer